EcoDrugPlus

Calcium Channel, Voltage-Dependent, Gamma Subunit 1a

Ensembl ID : ENSLCAG00010025209
Gene Symbol: CACNG1A
4 Cross references
194 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 3b

Ensembl ID : ENSLCAG00010002895
Gene Symbol: CACNG3B
3 Cross references
179 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 5a

Ensembl ID : ENSLCAG00010025220
Gene Symbol: CACNG5A
4 Cross references
184 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSLCAG00010024573
Gene Symbol: CACNG7A
4 Cross references
184 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 8a

Ensembl ID : ENSLCAG00010024575
Gene Symbol: CACNG8A
1 Cross references
167 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSLCAG00010007265
Gene Symbol: CASR
4 Cross references
202 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSLCAG00010011432
Gene Symbol: CACNA2D1
4 Cross references
226 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSLCAG00010011463
Gene Symbol: CACNA2D2
1 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSLCAG00010020288
Gene Symbol: CACNA2D3
4 Cross references
214 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSLCAG00010012209
Gene Symbol: CACNA2D4
1 Cross references
234 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSLCAG00010017252
Gene Symbol: CACNA2D4
2 Cross references
234 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSLCAG00010018362
Gene Symbol: CACNB3
1 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).